Targeted synthetic drugs

AB1150 TYPE I INTERFERON ACTIVATION OF MONOCYTES IN SYSTEMIC SCLEROSIS IS CGAS-STING DEPENDENT AND CAN BE DIRECTLY INDUCED BY DERMAL FIBROBALSTS: A PROMISING THERAPEUTIC TARGET
S. Di Donato, R. Ross, C. W. Wasson, J. Schmitz, J. Li, S. Visvanathan, F. Del Galdo

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1908; DOI: 10.1136/annrheumdis-2024-eular.4986
AB1030 JAK INHIBITORS’ EFFICACY AND SAFETY IN SYSTEMIC LUPUS ERYTHEMATOSUS: SYSTEMATIC REVIEW AND META-ANALYSIS
R. Dos-Santos, C. Porto, E. Perez-Pampín, J. R. Maneiro, P. Castro-Santamaria, M. Sanchez-Wonenburger, J. L. Puga-Guzmán, A. Mata, I. Álvarez, E. Campos, A. Mera Varela

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1834-1835; DOI: 10.1136/annrheumdis-2024-eular.1375
AB0940 UPADACITINIB IN AXIAL SPONDYLOARTHRITIS: THERAPEUTIC POSSIBILITIES AND PERSPECTIVES IN REAL WORLD CLINICAL PRACTICE
T. Shivacheva, Z. Apostolova, S. Bogdanova-Petrova, S. Dimitrov, G. Gerganov, R. Moraliyska, S. Hristova, T. Georgiev

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1780-1781; DOI: 10.1136/annrheumdis-2024-eular.1315
AB0947 DO MORE THERAPEUTIC OPTIONS LEAD TO A DECLINE IN THE RETENTION RATE OF BIOLOGICALS? A REAL-WORLD STUDY IN PSORIATIC ARTHRITIS AND SPONDYLOARTHRITIS PATIENTS
R. De Jong, M. Nurmohamed, A. Van Kuijk

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1785-1786; DOI: 10.1136/annrheumdis-2024-eular.2884
AB0752 CONTRIBUTION OF SECRETED SYNOVIAL TISSUE PROTEINS TO SERUM INFLAMMATORY PROFILES, CLINICAL FEATURES, AND THERAPEUTIC RESPONSES IN RHEUMATOID ARTHRITIS PATIENTS
C. Lopez-Pedrera, C. Perez-Sanchez, S. Corrales-Díaz Flores, L. Muñoz-Barrera, R. Ortega-Castro, J. Calvo-Gutiérrez, C. Aranda-Valera, M. L. Ladehesa-Pineda, I. Sanchez-Pareja, M. C. Ábalos-Aguilera, D. Ruíz-Vilchez, C. Merlo-Ruiz, M. Á. Aguirre-Zamorano, C. López-Medina, N. Barbarroja, T. Cerdó, M. Alarcon-Riquelme, A. Escudero-Contreras

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1667-1668; DOI: 10.1136/annrheumdis-2024-eular.5031
AB0777 IDENTIFICATION OF A MICRORNA SIGNATURE PREDICTIVE OF CLINICAL RESPONSE TO TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS
E. Celletti, M. DI Penta, E. Sabatini, D. De Cesare, A. Dionisi, F. Cipollone

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1681; DOI: 10.1136/annrheumdis-2024-eular.3970
AB0782 IN VITRO EFFECT OF UPADACITINIB AND TOFACITINIB ON PERIPHERAL BLOOD LEUKOCYTES FROM PATIENTS WITH EARLY AND ESTABLISHED RHEUMATOID ARTHRITIS
R. L. Teixeira, C. A. Bento, C. Tomé, V. C Romão, J. E. Fonseca, I. Alcobia, R. A. Moura

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1683-1684; DOI: 10.1136/annrheumdis-2024-eular.5197
AB0785 EFFICACY OF BIOLOGIC AND TARGETED SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE TREATMENT OF SARCOIDOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
K. Bechman, K. He, A. Miracle, K. Biddle, J. Galloway

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1685; DOI: 10.1136/annrheumdis-2024-eular.3065
AB0653 IMPACT OF TSDMARD, TOFACITINIB, ON ENDOTHELIAL FUNCTION IN RA AND ITS ASSOCIATION WITH CELLULAR RATIOS
A. Syngle, I. Verma, K. Chauhan

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1612-1613; DOI: 10.1136/annrheumdis-2024-eular.4054
AB0654 NEUTROPHIL-TO-LYMPHOCYTE RATIO, LEUKOCYTIC FORMULA REVERSAL AND PREVALENCE OF LARGE GRANULAR T LYMPHOCYTE LEUKEMIA IN AN ITALIAN MONOCENTRIC RHEUMATOID ARTHRITIS COHORT
DI Taranto, A. Amati, G. Cincinelli, L. Giudice, M. Biggioggero, M. Manara, F. Ingegnoli, E. G. Favalli, R. F. Caporali

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1613-1614; DOI: 10.1136/annrheumdis-2024-eular.4151

Main menu

Targeted synthetic drugs

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Targeted synthetic drugs

Pages